Naphazoline

Evidence Level: L5

Predicted Indications: 10

Naphazoline

Pharmacist Assessment Report

Naphazoline: From Ocular Redness Relief to Hypotrichosis Simplex of the Scalp

One-Sentence Summary

Naphazoline is a topical alpha-adrenergic vasoconstrictor, marketed in India as an eye drop that temporarily reduces eye redness. The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, but no clinical trials and no publications support this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Temporary relief of eye redness (vasoconstrictor eye drop). The licence records contain no approved indication text; this is taken from pharmacology data compiled for this report.
Predicted New Indication	Hypotrichosis simplex of the scalp
TxGNN Prediction Score	0.9983
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the compiled data. Pharmacology records show that naphazoline binds alpha-1A, alpha-2A and alpha-2C adrenoceptors. It is a vasoconstrictor that narrows swollen blood vessels in the eye.

The prediction is not mechanistically supported. Hypotrichosis simplex of the scalp is a genetic disorder of hair development. A vasoconstrictor has no known way to change its underlying pathology. If anything, constricting scalp vessels could reduce follicle perfusion.

The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Supporting this view, the other top-ranked predictions include both hair-loss conditions (congenital hypotrichosis, alopecia areata, alopecia) and hair-overgrowth conditions (hypertrichosis). They also include unrelated congenital malformation syndromes. These predictions contradict one another, which suggests nonspecific scoring.

The one prediction with some ophthalmic plausibility is open-angle glaucoma. Alpha-agonists such as brimonidine lower intraocular pressure. Naphazoline is not an established IOP-lowering agent, however, and the retrieved paper does not study it.

Literature Evidence

For the lead prediction, hypotrichosis simplex of the scalp, no related literature is currently available.

The only paper retrieved for any top-ranked prediction concerns a different drug class:

PMID	Year	Type	Journal	Key Findings
1295525	1992	Other (laser/corticosteroid study)	Aust N Z J Ophthalmol	Compared topical steroids and a non-steroid medication after argon laser trabeculoplasty for peripheral anterior synechiae and IOP. It does not study naphazoline and was retrieved for open-angle glaucoma (rank 8), not the lead prediction.

Clinical Trial Evidence

Currently no related clinical trials are registered for hypotrichosis simplex of the scalp, or for any of the other top 10 predicted indications.

India Market Information

Naphazoline has 20 valid single-ingredient registrations and no combination or cancelled registrations. All are ophthalmic products. The records contain no approved indication text. The five main authorizations are:

Authorization Number	Product Name	Dosage Form	Approved Indication
164326	Opti Zee Eye Drop	Packet of 10 ml eye drop	Not stated
151757	Nefcoz Eye Drop	Bottle of 10 ml eye drop	Not stated
162589	Optizee Plus Eye Drop	Packet of 10 ml eye drop	Not stated
156983	Nizoline Z Eye Drop	Packet of 5 ml eye drop	Not stated
137052	Mil Eye Drop	Packet of 10 ml eye drop	Not stated

Safety Considerations

Contraindications (not label text): The following conditions are listed as cautions for naphazoline:
- hypertension and other cardiovascular or heart disease
- hyperglycaemia, diabetes mellitus and diabetic ketoacidosis
- angle-closure glaucoma
- hyperthyroidism, Graves disease and thyrotoxicosis
- eye infections and conjunctivitis
Glaucoma concern: Sympathomimetic vasoconstrictors can cause mydriasis and are used cautiously in narrow-angle glaucoma. This matters for the glaucoma-related predictions (primary hereditary glaucoma and open-angle glaucoma).
Drug interactions: No drug-drug interactions were identified. The compiled data lists only pharmacological targets: alpha-1A, alpha-2A and alpha-2C adrenoceptors in humans, and the Taar4 gene in mouse.

Package insert warnings and contraindications could not be obtained, so please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a model score, with no clinical trials or literature. It also has no plausible mechanism, and vasoconstriction could be counterproductive for hair follicles. The drug is marketed in India only as an ophthalmic product, and the available safety data are limited.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian regulatory records (a blocking gap for safety screening)
Mechanism of action data from DrugBank
Preclinical or mechanistic evidence that an alpha-adrenergic agonist can affect hair follicle biology
Route compatibility assessment, since only ophthalmic products are marketed and any scalp use would need a new formulation
If the project is redirected, a targeted literature search on alpha-agonists and intraocular pressure, with attention to the angle-closure risk
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.